Danielle Bucco


Standard of Care Continues to Shift in RCC

May 11th 2018

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Frontline Treatment in Ovarian Cancer Could Undergo Transformation

May 10th 2018

Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.

Following FDA Approvals, CML Pipeline Has Challenges

April 25th 2018

Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.

Hamlin Discusses Practice-Changing Data in Lymphoma

April 25th 2018

Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.

CAR T-Cell Therapy Starts to Enter MCL Space

April 23rd 2018

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

Expert Highlights Advances Across Lymphoma Subtypes

April 23rd 2018

Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.

Role of PARP Inhibitors in Breast Cancer Continues to Be Refined

April 20th 2018

Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

Diet Linked With Tumor Aggressiveness in Endometrial Cancer

April 19th 2018

Lindsay West, MD, discusses the relationship between low-fat or high-fat diets and endometrial cancer and how these can be investigated further.

PV Treatment Landscape Balancing Effective Regimens With QOL Challenges

April 18th 2018

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

Giant of Cancer Care Shares Insights on Adjuvant Therapy in Melanoma

April 18th 2018

Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.